Femto Technologies Inc. FMTOF

Femto Technologies Inc. (FMTOF) announces U.S. launch of Sensera, a next-generation femtech device. U.S. launch of next-generation femtech device marks major product rollout boosting competitive positioning and revenue potential.

Femto Technologies Inc. (FMTOF) has been notified by The Nasdaq Stock Market regarding the delisting of its securities due to non-compliance with listing requirements. The company has been given a period to appeal the decision or take necessary actions to regain compliance. This situation raises concerns about the company's future operations and market presence. Delisting from Nasdaq significantly impacts investor sentiment and the company's ability to raise capital.

Femto Technologies Inc. (OTC: FMTOF) has announced positive results from a pre-launch user experience study of its Sensera device. The study indicates strong user satisfaction and engagement, suggesting that the device may meet market expectations upon its launch. This development is seen as a promising step forward for the company as it prepares to introduce the Sensera device to consumers. Positive user experience results indicate significant potential for the Sensera device's market introduction and overall company trajectory.

Femto Technologies Inc. (OTCID: FMTOF) has filed a notice of appeal against the Nasdaq Hearing Panel's decision to delist its shares. The company plans to submit a full statement of grounds to the Nasdaq Listing and Hearing Review Council, asserting that it has valid factual and legal arguments for reinstatement. Femto Technologies focuses on AI-driven wellness technology, including its product Sensera, which has received recognition at the CES Innovation Awards 2025. The appeal against the delisting decision could significantly impact the company's market presence and investor sentiment.

Femto Technologies Inc. (FMTO) will be delisted from Nasdaq on June 23, 2025, following a decision by the Nasdaq Hearings Panel. The company's shares will then trade on the OTC market. Femto is exploring options, including an appeal and potential listings on Canadian or European exchanges, but believes its stable financial condition will mitigate any operational impacts from the delisting. Femto is known for its AI-driven wellness technology, including the Sensera device, which has received recognition at the CES Innovation Awards 2025. The delisting from Nasdaq may affect market sentiment and visibility, but the company's stable financial condition suggests limited long-term impact.

Femto Technologies Inc. (FMTO) has announced a stock repurchase program authorized by its Board of Directors, allowing the company to buy back up to 43,025 subordinate voting shares, representing 5% of its outstanding shares. The program will start on May 20, 2025, and is expected to last for six months, with no obligation to repurchase a specific number of shares. CEO Yftah Ben Yaackov stated that the initiative aims to enhance shareholder value and reflects confidence in the company's ability to generate free cash flow. The repurchases will be funded from existing cash and cash equivalents. The stock repurchase program is expected to moderately influence shareholder value and market sentiment.

Femto Technologies Inc. (Nasdaq: FMTO) announced that the U.S. Patent and Trademark Office has granted a Notice of Allowance for its Sensera design, a female treatment device. This achievement highlights Femto's commitment to AI-driven wellness solutions and follows the recognition of Sensera as a CES Innovation Awards 2025 honoree in the AI category. CEO Yftah Ben Yaackov emphasized the significance of this milestone and the company's focus on innovative Femtech products. Femto's proprietary Smart Release System technology underpins its product development, ensuring efficacy and safety through rigorous testing and regulatory compliance. The patent allowance and CES recognition are significant advancements that could enhance Femto's market position and investor sentiment.

Femto Technologies Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for its proprietary Smart Release System technology, indicating that the patent application has passed examination and is likely to be granted. This development is a significant step towards protecting the company's innovative technology and could enhance its competitive position in the market. The patent allowance is expected to significantly impact Femto Technologies' competitive positioning and market opportunities.

Femto Technologies Inc. has closed a private placement of approximately $17 million, selling 4,076,736 Common Units at $4.17 each. The offering includes Common Shares, pre-funded warrants, and Series A and B Warrants with varying exercise prices and terms. The funds will be used for general corporate purposes and working capital. The transaction was facilitated by Aegis Capital Corp., and the securities sold are not registered under the Securities Act, limiting their resale. Femto's product, Sensera, aims to enhance feminine wellness and has received recognition in the CES Innovation Awards 2025. The significant capital raised will support product development and corporate growth, impacting future performance and market positioning.

Dr. Alexandra Dubinskaya has joined Femto Technologies Inc.'s Sensera as a Medical Advisor. Her expertise in medical technology and experience in clinical research are expected to enhance the company's capabilities in developing innovative healthcare solutions. This strategic appointment aims to strengthen Femto's position in the medical technology sector and drive future growth. The addition of a qualified medical advisor is likely to significantly impact Femto's strategic direction and product development in the healthcare market.

Femto Technologies Inc. to showcase Sensera at CES 2025 ShowStoppers(R) Event. The showcase of Sensera at a prestigious event like CES 2025 is likely to have a significant impact on Femto Technologies Inc.'s future and market performance.

Femto Technologies Inc. (BCAN) wins CES 2025 AI Innovation Award for Sensera femtech product. The award recognition is a significant achievement that could boost Femto's market position and investor sentiment.

Femto Technologies Inc. (BCAN) regains compliance with Nasdaq minimum bid price requirement after maintaining a minimum closing bid price of $1.00 per share for 10 consecutive business days. Regaining compliance with Nasdaq minimum bid price requirement is expected to moderately influence the company's financial performance and market sentiment.

Femto Technologies Inc. submits flagship product to CES Innovation Awards competition, showcasing advanced technology for feminine wellness. The article highlights a significant milestone in Femto's journey with potential to redefine the company's competitive position and long-term prospects.

Femto Technologies Inc. partners with FDA-registered manufacturer to launch flagship AI-driven FemTech product's pods, aiming for FDA approval. The partnership with an FDA-registered facility for 510(k) lubricants and FDA approval process for the flagship product indicate a significant impact on Femto Technologies Inc.'s future and market performance.

Femto Technologies Inc. is conducting a consumer study on feminine intimacy habits in the US, focusing on wellness issues and technology use. The company's flagship product utilizes advanced technology and user-centric design to promote holistic wellness. The article discusses Femto's innovative approach to addressing women's health needs and the potential impact of their technology on the market.

Femto Technologies Inc. to introduce flagship feminine wellness product at CES 2025, showcasing advanced technology and user-centric design. The introduction of a groundbreaking product with advanced technology and user-centric design is expected to have a significant impact on Femto Technologies Inc.'s future and market performance.

Femto Technologies Inc. reports increase in revenue and transition to net profit for the second quarter of 2024. Significant impact likely on future and performance due to the company's improved financial results and transition to net profit.

Femto Technologies Inc. reports increase in revenue and transition to net profit for the second quarter of 2024. The financial results show a significant improvement in revenue and profitability, indicating a potential shift in the company's trajectory.

Femto Technologies Inc. to introduce flagship feminine wellness product at The AVN Expo in Las Vegas, showcasing advanced SRS technology for women's health and wellbeing. The introduction of a groundbreaking product with advanced technology and focus on women's health is expected to have a significant impact on BYND Cannasoft Enterprises Inc.'s future and market performance.

BYND Cannasoft Enterprises Inc. changes its name to Femto Technologies Inc. and launches new website. Femto focuses on women's wellness and lifestyle products with innovative technology. The name change and focus on women's wellness products with innovative technology are expected to significantly impact the company's future trajectory and market performance.

BYND Cannasoft Enterprises Inc. provided CEO update for 2024, focusing on FemTech market growth and innovative product line-up, patent protection, market penetration stages, and user survey results. The article outlines significant strategic moves, product developments, patent protection, and market penetration plans that could fundamentally alter the company's trajectory and investor sentiment.

BYND Cannasoft Enterprises focuses on significant growth in the $7 billion CBD market in 2023, particularly in personal care products. The article describes major strategic moves and significant product launches that are expected to significantly alter the company's trajectory and investor sentiment.

BYND Cannasoft expands research and development efforts to develop smart products for women's sports, hair, and cosmetics sectors. Expansion into fem-tech market with innovative product line-up is expected to have a significant impact on future performance and market positioning.

BYND Cannasoft Enterprises suspends plans for medical cannabis facility and focuses on Femtech sector. The decision to shift focus to Femtech sector and suspend cannabis facility construction is a significant strategic move that could reshape the company's trajectory.

BYND Cannasoft Enterprises Inc. implemented a 1-for-190 reverse stock split to regain compliance with Nasdaq listing requirements. The reverse stock split may moderately influence the company's financial performance and market positioning.

Aegis Capital Corp. acted as Sole Bookrunner on a $7.0 Million Underwritten Public Offering for BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN). The underwritten public offering of $7.0 million by a reputable bookrunner is a significant move that could have a major impact on the future and market performance of BYND Cannasoft Enterprises Inc.

BYND Cannasoft Enterprises Inc. closed a $7.0 million underwritten public offering. The significant amount raised through the public offering is expected to have a major impact on the company's future financial performance and strategic direction.

BYND Cannasoft Enterprises Inc. priced a $7.0 million underwritten public offering. The public offering is a significant move that could impact the company's future trajectory and market performance.

BYND Cannasoft team in China to sign production agreements for EZ-G device and capsules. Signing production agreements with large manufacturers in China for EZ-G device and capsules is a significant strategic move that can impact future sales and profits.